CDKN2A is known to be a negative regulator of the cell cycle, and its transcriptional variants (p16INK4a, p14ARF and p12) showed different inhibitory effects on the A549 human lung cancer cell line [31]. This evidence concerns the gene CDKN2A and lung carcinoma.